Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon […]
Read MorePharmalittle: Lilly expands retatrutide access, Gilead wins in court
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and […]
Read MoreA tragic paradox, Gilead updates, and lots of Pfizer news
Adam Feuerstein/STAT Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, […]
Read More